Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Support for next-gen cardiac CT scanners

You may also be interested in...



International News In Brief

St. Jude Brio pulled from overseas markets. Another U.K. metal-on-metal hip alert. More international device news.

Europe In Brief

MHRA annual report: The U.K. Medicines and Healthcare products Regulatory Agency's July 14 annual 1report notes the agency entered nearly 100% of fatal and serious adverse event incidents involving medical devices into its Adverse Event Tracking System within three days of receiving the adverse event report; all but one of the 8,909 fatal or serious device adverse event reports were available on the database within three days. In addition, MHRA fully achieved its 2008/09 performance goal of publishing medical device alerts within 60 days of a decision to issue such an alert, and within 20 days for "immediate action" device alerts

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel